These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 38755632

  • 1. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T, Dunga S, Makonokaya L, Woelk G, Maida A, Wang A, Ahimbisibwe A, Chamanga RK, Zimba SB, Kayira D, Machekano R.
    BMC Public Health; 2024 May 16; 24(1):1321. PubMed ID: 38755632
    [Abstract] [Full Text] [Related]

  • 2. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J.
    HIV Med; 2024 Jul 16; 25(7):826-839. PubMed ID: 38520085
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I, Katana E, Agnes Odongpiny EL, Nalugga EA, Castelnuovo B, Fowler MG, Musoke P.
    AIDS Res Ther; 2024 Apr 18; 21(1):23. PubMed ID: 38637785
    [Abstract] [Full Text] [Related]

  • 4. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, Gill J, Rabkin CS, Gange SJ, Horberg MA, Margolick J, Li J, Wong C, Willig A, Lima VD, Crane H, Thorne J, Silverberg M, Kirk G, Mathews WC, Sterling TR, Lake J, Koethe JR, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).
    J Int AIDS Soc; 2020 Apr 18; 23(4):e25484. PubMed ID: 32294337
    [Abstract] [Full Text] [Related]

  • 5. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.
    Makonokaya L, Maida A, Kalitera LU, Wang A, Kapanda L, Kayira D, Bottoman M, Nkhoma H, Dunga S, Joaki Z, Chamanga R, Nkanaunena K, Hrapcak S, Nyirenda R, Chiwandira B, Maulidi M, Woelk G, Machekano R, Maphosa T.
    AIDS Behav; 2024 Jun 18; 28(6):2148-2155. PubMed ID: 38615099
    [Abstract] [Full Text] [Related]

  • 6. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, Moore RD, Eron JJ, Geng E, Mathews WC, Rodriguez B, Willig AL, Burkholder GA, Lindström S, Wood BR, Collier AC, Vannappagari V, Henegar C, Van Wyk J, Curtis L, Saag MS, Kitahata MM, Delaney JAC.
    J Acquir Immune Defic Syndr; 2021 Mar 01; 86(3):339-343. PubMed ID: 33148997
    [Abstract] [Full Text] [Related]

  • 7. Weight Gain Among Treatment-Naïve Persons With HIV Receiving Dolutegravir in Kenya.
    Bourgi K, Ofner S, Musick B, Griffith B, Diero L, Wools-Kaloustian K, Yiannoutsos CT, Gupta SK.
    J Acquir Immune Defic Syndr; 2022 Dec 15; 91(5):490-496. PubMed ID: 36126175
    [Abstract] [Full Text] [Related]

  • 8. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    J Int AIDS Soc; 2024 Feb 15; 27(2):e26216. PubMed ID: 38332525
    [Abstract] [Full Text] [Related]

  • 9. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A, Kusejko K, Johnson LF, Günthard HF, Riou J, Wandeler G, Egger M, Kouyos RD.
    PLoS Med; 2020 Dec 15; 17(12):e1003397. PubMed ID: 33315863
    [Abstract] [Full Text] [Related]

  • 10. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, Koethe JR, Sterling TR.
    Clin Infect Dis; 2020 Mar 17; 70(7):1267-1274. PubMed ID: 31100116
    [Abstract] [Full Text] [Related]

  • 11. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
    Guaraldi G, Calza S, Milic J, Calcagno A, Focà E, Rota M, Renzetti S, Celotti A, Siano M, Celesia BM, Piconi S, de Socio GV, Cattelan AM, Orofino G, Riva A, Nozza S, di Perri G.
    AIDS; 2021 May 01; 35(6):939-945. PubMed ID: 33635844
    [Abstract] [Full Text] [Related]

  • 12. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M, Butel C, Comlan AS, Konou AA, Tegueni K, Ehlan A, Lack F, Dossim S, Ayouba A, Delaporte E, Dagnra AY, Peeters M.
    AIDS; 2020 Apr 01; 34(5):783-787. PubMed ID: 31895149
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
    Chu C, Tao K, Kouamou V, Avalos A, Scott J, Grant PM, Rhee SY, McCluskey SM, Jordan MR, Morgan RL, Shafer RW.
    Viruses; 2024 Mar 04; 16(3):. PubMed ID: 38543764
    [Abstract] [Full Text] [Related]

  • 14. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
    Kouamou V, Washaya T, Mapangisana T, Ndhlovu CE, Manasa J.
    AIDS; 2024 Apr 01; 38(5):689-696. PubMed ID: 38227596
    [Abstract] [Full Text] [Related]

  • 15. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
    Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, Nazziwa E, Nabukenya M, Sewanyana I, Balaba J, Ntale J, Calnan J, Birabwa E, Akao J, Mwangi C, Naluguza M, Ahimbisibwe A, Katureebe C, Nabadda S, Nelson L, Dirlikov E.
    PLoS One; 2024 Apr 01; 19(6):e0305129. PubMed ID: 38923981
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A, Icona Foundation Study Group.
    J Int AIDS Soc; 2019 Jan 01; 22(1):e25227. PubMed ID: 30663278
    [Abstract] [Full Text] [Related]

  • 17. An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol.
    Abrams EJ, Jao J, Madlala HP, Zerbe A, Catalano P, Gerschenson M, Goedecke JH, Gomba Y, Josefson J, Kurland IJ, Legbedze J, McComsey GA, Matyesini S, Mukonda E, Robinson D, Myer L.
    PLoS One; 2024 Jan 01; 19(8):e0307296. PubMed ID: 39159183
    [Abstract] [Full Text] [Related]

  • 18. Weight gain during the dolutegravir transition in the African Cohort Study.
    Esber AL, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J, Singoei V, Maswai J, Dear NF, Crowell TA, Polyak CS, Ake JA, AFRICOS Study Group.
    J Int AIDS Soc; 2022 Apr 01; 25(4):e25899. PubMed ID: 35419973
    [Abstract] [Full Text] [Related]

  • 19. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
    Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM.
    J Acquir Immune Defic Syndr; 2019 Aug 15; 81(5):572-577. PubMed ID: 31107299
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
    Nasreddine R, Florence E, Vandercam B, Moutschen M, Goffard JC, De Munter P, Delforge M, Marinus W, De Wit S, Belgian Research on AIDS and HIV Consortium (BREACH).
    AIDS; 2020 Jul 01; 34(8):1151-1159. PubMed ID: 32287063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.